Polymorphic behavior of gram-negative bacteria membranes

V. L. Borovjagin,A. Sabelnikov,Y. S. Tarahovsky,I. Vasilenko

DOI: https://doi.org/10.1007/BF02209154

1987-12-01

Abstract:

What problem does this paper attempt to address?

Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy

Franziska Hopfner,Nora Möhn,Britta Eiz-Vesper,Britta Maecker-Kolhoff,Jens Gottlieb,Rainer Blasczyk,Nima Mahmoudi,Kaweh Pars,Ortwin Adams,Martin Stangel,Mike P Wattjes,Günter Höglinger,Thomas Skripuletz

DOI: https://doi.org/10.1212/NXI.0000000000001020

2021-05-17

Abstract:Objective: Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating opportunistic infection of the brain caused by the ubiquitously distributed JC polyomavirus. There are no established treatment options to stop or slow down disease progression. In 2018, a case series of 3 patients suggested the efficacy of allogeneic BK virus-specific T-cell (BKV-CTL) transplantation. Methods: Two patients, a bilaterally lung transplanted patient on continuous immunosuppressive medication since 17 years and a patient with dermatomyositis treated with glucocorticosteroids, developed definite PML according to AAN diagnostic criteria. We transplanted both patients with allogeneic BKV-CTL from partially human leukocyte antigen (HLA) compatible donors. Donor T cells had directly been produced from leukapheresis by the CliniMACS IFN-γ cytokine capture system. In contrast to the previous series, we identified suitable donors by HLA typing in a preexamined registry and administered 1 log level less cells. Results: Both patients' symptoms improved significantly within weeks. During the follow-up, a decrease in viral load in the CSF and a regression of the brain MRI changes occurred. The transfer seemed to induce endogenous BK and JC virus-specific T cells in the host. Conclusions: We demonstrate that this optimized allogeneic BKV-CTL treatment paradigm represents a promising, innovative therapeutic option for PML and should be investigated in larger, controlled clinical trials. Classification of evidence: This study provides Class IV evidence that for patients with PML, allogeneic transplant of BKV-CTL improved symptoms, reduced MRI changes, and decreased viral load.
A comparison between the direct and the indirect fractional order closed-loop bias eliminated least squares method

Z. Yakoub,M. Chetoui,M. Amairi,M. Aoun

DOI: https://doi.org/10.1109/STA.2016.7951978

2016-12-01

Abstract:This paper deals with the fractional closed-loop system identification. A comparison between the direct and the indirect approach is processed. The fractional order bias eliminated least squares method is used to identify the fractional closed-loop transfer function. This method is founded on the ordinary least squares method and the state variable filter. A numerical example is treated to show the efficiency of each approach and discuss results.
Beyond antivirals: virus-specific T-cell immunotherapy for BK virus haemorrhagic cystitis and JC virus progressive multifocal leukoencephalopathy

Adam S Nelson,Niveditha Yalamarthi,Michelle K Yong,Emily Blyth

DOI: https://doi.org/10.1097/QCO.0000000000000794

2021-12-01

Abstract:Purpose of review: The clinical manifestations of the polyomaviruses BK and JC in immunocompromised patients include BK virus (BKV) induced haemorrhagic cystitis and nephropathy, and JC virus (JCV) associated progressive multifocal leukoencephalopathy (PML) and are typically a consequence of impaired adaptive immunity in the host. To date, little clinical success has been achieved with antiviral agents or other drug therapies to treat these conditions. Here we review the methods and outcomes of the most recent clinical studies utilising adoptive immunotherapy with BK and/or JC virus-specific T-cells (VST) as either prophylaxis or treatment alternatives. Recent findings: In the last 12-18 months, several clinical trials have been published in the post-haemopoietic stem cell transplant (HSCT) setting showing good clinical success with the use of VST for treatment of BK viremia ± haemorrhagic cystitis. Between 82 and 100% clinical response has been observed in haemorrhagic cystitis using either third-party or donor-derived VST. The therapy was well tolerated with few cases of graft versus host disease in HSCT recipients, but immune mediated renal allograft loss was observed in one renal transplant recipient. Studies using BKV/JCV VST to treat PML are hindered by few patients who are sufficiently stable to receive VST. In a condition that otherwise carries such poor prognosis, VST were associated with clearance of JC virus, clinical and radiological improvement in some patients. Immune reconstitution inflammatory syndrome was a noted adverse event. Summary: Restoration of BK and JC virus immunity using VST immunotherapy has shown good clinical outcomes in BKV associated infections. Further evaluation with the administration of VST earlier in the course of disease is warranted for the treatment of BKV associated nephropathy in renal allograft and in JCV PML. In both indications, larger cohorts and standardisation of dosing and outcome measures would be of benefit.
Antigen-Specific T Cell Receptor Discovery for Treating Progressive Multifocal Leukoencephalopathy

Sasha Gupta,Tijana Martinov,Ashley Thelen,Megumi Sunahara,Shwetha Mureli,Angie Vazquez,Josiah Gerdts,Ravi Dandekar,Irene Cortese,Camille Fouassier,Elaine Schanzer,Fyodor D Urnov,Alex Marson,Brian R Shy,Philip D Greenberg,Michael R Wilson

DOI: https://doi.org/10.1101/2024.11.04.621904

2024-11-04

Abstract:Background: Progressive multifocal leukoencephalopathy (PML) is a frequently fatal disease of the central nervous system caused by JC virus (JCV). Survival is dependent on early diagnosis and ability to re-establish anti-viral T cell immunity. Adoptive transfer of polyomavirus-specific T cells has shown promise; however, there are no readily available HLA-matched anti-viral T cells to facilitate rapid treatment. Objective: Identify epitopes of the JCV major capsid protein VP1 that elicit an immune response in the context of human leukocyte antigen allele A*02:01 (HLA-A2) and isolate cognate T cell receptors (TCRs) from healthy donors. Evaluate individual VP1-specific TCRs for their capacity to be expressed in T cells and clear JCV in vitro. Methods: PBMCs from HLA-A2+ healthy donors were stimulated with peptide libraries tiled across the JCV VP1 protein. Multiple rounds of stimulation were performed to identify the antigens that induced the largest expansion and CD8+ T cell response (measured as INFg;, TNFa;, CD137, and CD69 expression). High-affinity, antigen-specific CD8+ T cells were isolated based on intensity of tetramer binding for downstream single-cell TCR sequencing. Candidate TCRs were selected based on tetramer binding affinity and activation assays. Promising TCRs were introduced into the T cell genome via viral transduction for in vitro validation including peptide-pulsed K562 cells and astrocyte cells, and JCV-infected astrocytes. Results: Four conserved JCV VP1 epitopes (amino acids 100-108, 251-259, 253-262, and 274-283) presented by HLA-A2 were identified. VP1(100-108) consistently elicited the highest level of IFNg; production from multiple donors and this peptide is in a highly conserved region of VP1. We next identified fourteen high avidity TCRs specific for VP1(100-108). When virally transduced into primary human T cells, seven of these TCRs demonstrated specific binding to VP1(100-108):HLA-A2 tetramers, and four showed increased IFNg; response when incubated with peptide. Primary CD8+ T cells expressing two of these TCRs cleared both HLA-A2 positive K562 cells and HLA-A2 positive SVG astrocyte cell line presenting exogenously added VP1 peptide at a range of E:T ratios. In addition, both TCR-transduced T cell populations effectively lysed JCV-infected astrocytes. Conclusions: We identified JCV VP1 epitopes that are immunogenic in the context of HLA-A2 MHC-I, including epitopes that have not been previously described. The VP1(100-108) epitope was used to isolate HLA-A2-restricted TCRs. When cloned into primary human CD8+ T cells, these TCRs recognized VP1 (100-108)-presenting targets, and the transduced T cells conferred cytotoxic activity and eliminated K562 and astrocyte cells displaying the VP1(100-108) peptide and not sham peptide, as well as JCV-infected astrocytes. Taken together, these data suggest that JCV VP1-specific TCRs could be appealing therapeutics for HLA-A2+ individuals with PML in whom intrinsic T cell immunity cannot be rescued.

Neuroscience
Density functional theory calculations on the thermodynamic properties of polynitrosoprismanes

W. Chi,Guangdong Sun,T. Liu,Butong Li,Haishun Wu

DOI: https://doi.org/10.1007/s00894-012-1471-7

IF: 2.172

2012-05-30

Journal of Molecular Modeling

Abstract:
Case report: JC polyomavirus nephropathy in simultaneous heart–kidney transplantation: the role of viral-specific in situ hybridization staining

Bassam G. Abu Jawdeh,Maxwell L. Smith,Madeline R. Hudson,Girish K. Mour,Pooja Budhiraja,Julie L. Rosenthal

DOI: https://doi.org/10.3389/fmed.2023.1282827

IF: 3.9

2023-10-20

Frontiers in Medicine

Abstract:Introduction JC polyomavirus (JCPyV) is a ubiquitous virus that can be latent in the brain and the kidney. It is the etiologic agent responsible for progressive multifocal leukoencephalopathy, a fatal, demyelinating disease of the central nervous system, and rarely causes polyomavirus nephropathy in immunocompromised kidney transplant recipients. Case description We present the first case of JCPyV nephropathy in a simultaneous heart–kidney transplant patient, where viral-specific in situ hybridization staining of the kidney tissue was utilized to confirm the diagnosis. The patient was diagnosed 6 years after simultaneous heart–kidney transplantation and was treated with immunosuppression reduction and intravenous immunoglobulin. Discussion JCPyV nephropathy should be considered in the differential diagnosis of kidney allograft injury, particularly, with suggestive light microscopy histologic features in the absence of BK polyomavirus viremia and/or viruria. In addition to obtaining JCPyV PCR in the blood, in situ hybridization staining may have a utility in confirming the diagnosis. To date, we lack effective JCPyV-specific therapies, and prompt initiation of immunosuppression reduction remains the mainstay of treatment.

medicine, general & internal
Adenovirus‐ and cytomegalovirus‐specific adoptive T‐cell therapy in the context of hematologic cell transplan or HIV infection – A single‐center experience

Benedikt Obermaier,Christiane Braun,Luca Hensen,Osama Ahmad,Christoph Faul,Peter Lang,Wolfgang Bethge,Claudia Lengerke,Wichard Vogel

DOI: https://doi.org/10.1111/tid.14296

2024-06-05

Transplant Infectious Disease

Abstract:In this retrospective cohort, cytomegalovirus (CMV)‐ and adenovirus‐specific T‐cell therapy appear to be safe and effective. A first case of successful virus‐specific T‐cell therapy for CMV reactivation associated with advanced HIV infection encourages further evaluation of adoptive immunotherapy beyond the context of allogeneic hematopoietic cell transplantation. Background Reactivation of viral infections, in particular cytomegalovirus (CMV) and adenovirus (ADV), cause morbidity and non‐relapse‐mortality in states of immune deficiency, especially after allogeneic hematopoietic cell transplantation (allo‐HCT). Against the background of few available pharmacologic antiviral agents, limited by toxicities and resistance, adoptive transfer of virus‐specific T‐cells (VST) is a promising therapeutic approach. Methods We conducted a single‐center retrospective analysis of adult patients treated with ADV‐ or CMV‐specific T‐cells in 2012–2022. Information was retrieved by review of electronic health records. Primary outcome was a response to VST by decreasing viral load or clinical improvement. Secondary outcomes included overall survival and safety of VST infusion, in particular association with graft‐versus‐host disease (GVHD). Results Ten patients were included, of whom four were treated for ADV, five for CMV, and one for ADV‐CMV‐coinfection. Cells were derived from stem cell donors (6/10) or third‐party donors (4/10). Response criteria were met by six of 10 patients (4/4 ADV, 2/5 CMV, and 0/1 ADV‐CMV). Overall survival was 40%. No infusion related adverse events were documented. Aggravation of GVHD after adoptive immunotherapy was observed in two cases, however in temporal association with a conventional donor lymphocyte infusion and a stem cell boost, respectively. Conclusion In this cohort, CMV‐ and ADV‐specific T‐cell therapy appear to be safe and effective. We describe the first reported case of virus‐specific T‐cell therapy for CMV reactivation not associated with transplantation but with advanced HIV infection. This encourages further evaluation of adoptive immunotherapy beyond the context of allo‐HCT.

immunology,infectious diseases,transplantation
JCV granule cell neuronopathy: A rare case manifestation

Rumela Nayak,Shilpa Rao,Nirmala Subramanian

DOI: https://doi.org/10.5414/NP301639

2024-08-09

Abstract:Granule cell neuronopathy (GCN) caused by John Cunningham virus (JCV) is a rare yet significant neurological complication, particularly in immunocompromised individuals such as those with AIDS. We present a case of a 34-year-old HIV-positive male exhibiting classical symptoms of cerebellar dysfunction. Magnetic resonance imaging revealed demyelination suggestive of progressive multifocal leukoencephalopathy (PML). Histopathological examination confirmed JCV-GCN, characterized by lytic infection of cerebellar granule cell neurons. Among the 41 reported cases of JCV-GCN, histopathological data were available for only 10 cases. Ours is the 11th case with available histopathology. This case underscores the importance of considering JCV infection in the differential diagnosis of progressive cerebellar syndromes in immunocompromised patients. Early recognition and diagnosis are crucial for appropriate management and prognosis.
Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature

Martijn T Wijburg,Bob W van Oosten,Jean-Luc Murk,Ouafae Karimi,Joep Killestein,Mike P Wattjes

DOI: https://doi.org/10.1007/s00415-014-7530-5

Abstract:Granule cell neuronopathy (GCN) is a rare JC virus (JCV)-related disease in immunocompromised patients, characterized by lytic infection of the cerebellar granule cell layer. To enable early diagnosis and intervention, we identify features of GCN and describe possible aspects of disease heterogeneity. We report on two new cases of GCN in HIV-infected patients of whom we retrospectively assessed clinical and radiologic data. In addition, we carried out a literature search and review of clinical, radiologic and histopathologic findings of all published GCN cases. Including the two new cases reported here, a total of 18 GCN cases were included in this study. HIV infection, present in 12 of the cases, was the most common underlying condition, followed by monoclonal antibody treatment which was present in three cases. Cerebellar atrophy was detected in all except two cases. In 12 patients a heterogeneous distribution pattern of white matter changes in the cerebellum and brainstem was observed. Imaging findings in GCN are remarkably heterogeneous; exhibiting cerebellar atrophy, as well as white matter pathology, particularly in the adjacent infratentorial white matter. This suggests an overlap of GCN with other JCV-related diseases, such as progressive multifocal leukoencephalopathy.
Angina pectoris beim Leiomyom

A. Wilke,T. Kruse,B. Maisch

DOI: https://doi.org/10.1007/BF03044361

1998-08-01

Herz

Abstract:
Cell killing and mutagenesis by 8‐methoxypsoralen in mammalian (rodent) cells

C. Arlett,J. Heddle,B. Broughton,A. M. Rogers

DOI: https://doi.org/10.1111/j.1365-2230.1980.tb01683.x

1980-06-01

Abstract:The use of psoralens and near ultraviolet light (the PUVA regime) for the successful treatment of psoriasis is now widespread. Amongst its attractions are the avoidance of treatment with steroids or tar oil derivatives and long periods of hospitalization. Potential difficulties with the treatment include somatic or genetic hazards and possibly toxicity to the liver. Studies with both micro-organisms and mammalian cells in culture have shown that the combination of 8methoxypsoralen (8-MOP) with near ultraviolet light at 360 nm (UV-A), is mutagenic (Igali et al., 1970; Arlett, 1973 ^ Simons & Burger, 1977; Burger & Simons, 1979), thus there exists the potential for increased mutation and possible tumour formation in exposed regions of the body (Bridges, 1978). The realization of this expectation was shown dramatically in a group of xeroderma pigmentosum individuals subjected to a PUVA regime (Reed, 1976; Reed, Sugarman & Mathis, 1977). This particular observation is important since it may show us what can happen in an extreme case for normal individuals; it also provides further evidence for the importance of competent DNA repair mechanisms in the maintenance of human health (Arlett & Lehmann, 1978). A much less rigorous form of PUVA treatment has been used for many years in the management of vitiligo, but it is not known whether or not such patients ultimately show an enhanced frequency of skin tumours (Hopkins et al., 1963; MacDonald et al., 1963). A different type of risk, namely a possible increase in the frequency of mutations and tumours in tissues which have been treated with 8-MOP but received no light, was raised by observations with bacteria which showed that 8-MOP on its own was capable of mducing frameshift mutations (Clarke & Wade, 1975; Bridges & Mottershead, 1977). A particular
Achievement of disease control with donor-derived EB virus-specific cytotoxic T cells after allogeneic peripheral blood stem cell transplantation for aggressive NK-cell leukemia

Shojiro Haji,Motoaki Shiratsuchi,Takamitsu Matsushima,Akiko Takamatsu,Mariko Tsuda,Yasuhiro Tsukamoto,Emi Tanaka,Hirofumi Ohno,Eriko Fujioka,Yuriko Ishikawa,Ken-Ichi Imadome,Yoshihiro Ogawa

DOI: https://doi.org/10.1007/s12185-016-2131-y

Abstract:Aggressive NK-cell leukemia (ANKL) is characterized by systemic infiltration of Epstein-Barr virus (EBV)-associated natural killer cells and poor prognosis. We report a case of ANKL in which EBV-specific cytotoxic T lymphocytes (CTLs) were induced. A 41-year-old male suffered from fever, pancytopenia, and hepatosplenomegaly. The number of abnormal large granular lymphocytes in the bone marrow was increased and the cells were positive for CD56 and EBV-encoded small nuclear RNAs. The patient was diagnosed with ANKL and achieved a complete response following intensive chemotherapy. He then underwent allogeneic peripheral blood stem cell transplantation from his sister. Conditioning therapy consisted of total body irradiation and cyclophosphamide. Graft-versus-host disease prophylaxis consisted of cyclosporine and methotrexate. On day 31, complete donor chimerism was achieved and no acute graft-versus-host disease developed. The ANKL relapsed on day 80, and cyclosporine was rapidly tapered and chemotherapy was started. During hematopoietic recovery, the number of atypical lymphocytes increased, but they were donor-derived EBV-specific CTLs. The patient achieved a partial response and EBV viral load decreased to normal range. Unfortunately, ANKL worsen again when the CTLs disappeared from his blood. This is the first case report of ANKL in which induced EBV-specific CTLs may have contributed to disease control.
Differentiation of highly pathogenic strains of human JC polyomavirus in neurological patients by next generation sequencing

Eeva Auvinen,Anni Honkimaa,Pia Laine,Sara Passerini,Ugo Moens,Valeria Pietropaolo,Mika Saarela,Leena Maunula,Laura Mannonen,Olli Tynninen,Hannu Haapasalo,Tuomas Rauramaa,Petri Auvinen,Hanna Liimatainen

DOI: https://doi.org/10.1016/j.jcv.2024.105652

IF: 14.481

2024-02-14

Journal of Clinical Virology

Abstract:Background JC polyomavirus (JCPyV) persists asymptomatic in more than half of the human population. Immunocompromising conditions may cause reactivation and acquisition of neurotropic rearrangements in the viral genome, especially in the non-coding control region (NCCR). Such rearranged JCPyV strains are strongly associated with the development of progressive multifocal leukoencephalopathy (PML). Methods Using next-generation sequencing (NGS) and bioinformatics tools, the NCCR was characterized in cerebrospinal fluid (CSF; N=21) and brain tissue (N=16) samples from PML patients (N=25), urine specimens from systemic lupus erythematosus patients (N=2), brain tissue samples from control individuals (N=2) and waste-water samples (N=5). Quantitative PCR was run in parallel for diagnostic PML samples. Results Archetype NCCR (i.e. ABCDEF block structure) and archetype-like NCCR harboring minor mutations were detected in two CSF samples and in one CSF sample and in one tissue sample, respectively. Among samples from PML patients, rearranged NCCRs were found in 8 out of 21 CSF samples and in 14 out of 16 brain tissue samples. Complete or partial deletion of the C and D blocks was characteristic of most rearranged JCPyV strains. From ten CSF samples and one tissue sample NCCR could not be amplified. Conclusions Rearranged NCCRs are predominant in brain tissue and common in CSF from PML patients. Extremely sensitive detection and identification of neurotropic viral populations in CSF or brain tissue by NGS may contribute to early and accurate diagnosis, timely intervention and improved patient care.

virology
A hybrid model based on ANFIS and adaptive expectation genetic algorithm to forecast TAIEX

Liang-Ying Wei

DOI: https://doi.org/10.1016/J.ECONMOD.2013.06.009

2013-07-01

Abstract:
Biomarkers for progressive multifocal leukoencephalopathy: emerging data for use of JC virus DNA copy number in clinical trials

Irene Cortese,Gina Norato,Patrick R Harrington,Therri Usher,Ilaria Mainardi,Guillaume Martin-Blondel,Paola Cinque,Eugene O Major,Virginia Sheikh

DOI: https://doi.org/10.1016/s1474-4422(24)00099-1

IF: 59.935

2024-04-18

The Lancet Neurology

Abstract:Summary Progressive multifocal leukoencephalopathy is a rare but devastating demyelinating disease caused by the JC virus (JCV), for which no therapeutics are approved. To make progress towards addressing this unmet medical need, innovations in clinical trial design are needed. Quantitative JCV DNA in CSF has the potential to serve as a valuable biomarker of progressive multifocal leukoencephalopathy disease and treatment response in clinical trials to expedite therapeutic development, as do neuroimaging and other fluid biomarkers such as neurofilament light chain. Specifically, JCV DNA in CSF could be used in clinical trials as an entry criterion, stratification factor, or predictor of clinical outcomes. Insights from the investigation of candidate biomarkers for progressive multifocal leukoencephalopathy might inform approaches to biomarker development for other rare diseases.

clinical neurology
Efficacy of pp65‐specific TCR‐T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation

Guangna Liu,Hua Chen,Xingyu Cao,Lemei Jia,Wei Rui,Hongli Zheng,Daosheng Huang,Fang Liu,Yue Liu,Xueqiang Zhao,Peihua Lu,Xin Lin

DOI: https://doi.org/10.1002/ajh.26708

IF: 13.265

2022-08-29

American Journal of Hematology

Abstract:Cytomegalovirus (CMV) infection remains a major cause of mortality after hematopoietic stem cell transplantation (HSCT). Current treatments, including anti‐viral drugs and adoptive cell therapy with CMV‐specific cytotoxic T lymphocytes (CTLs),only show limited benefits in patients. T‐cell receptor (TCR)‐T cell therapy offers a promising option to treat CMV infections. Here, using tetramer‐based screening and single‐cell TCR cloning technologies, we identified various CMV antigen‐specific TCRs from healthy donors, and generated TCR‐T cells targeting multiple pp65 epitopes corresponding to three major HLA‐A alleles. The TCR‐T cells showed efficient cytotoxicity towards epitope‐expressing target cells in vitro. After transfer into immune‐deficient mice bearing pp65+HLA+ tumor cells, TCR‐T cells induced dramatic tumor regression and exhibited long‐term persistence. In a phase I clinical trial (NCT04153279), CMV TCR‐T cells were applied to treat patients with CMV reactivation after HSCT. Except one patient who withdrew at early treatment stage, all other 6 patients were well‐tolerated and achieved complete response (CR), no more than grade 2 cytokine release syndrome (CRS) and other adverse events were observed. CMV TCR‐T cells persisted up to 3 months. Among them, 2 patients have survived for more than one year. This study demonstrates the great potential in the treatment and prevention of CMV infection following HSCT or other organ transplantation. This article is protected by copyright. All rights reserved.

hematology
GPCR Inhibitors Have Antiviral Properties against JC Polyomavirus Infection

Sandberg,Bond,Bennett,Craig,Winski,Kirkby,Kraemer,Kelly,Hess,Maginnis

DOI: https://doi.org/10.3390/v16101559

2024-10-01

Viruses

Abstract:JC polyomavirus (JCPyV) infects the majority of the population and initially establishes a persistent but asymptomatic infection of the kidneys. In healthy individuals, the infection remains controlled by the host immune system, but for individuals experiencing prolonged immunosuppression, the infection can reactivate and spread to the brain, where it causes progressive multifocal leukoencephalopathy (PML), which is a fatal neurodegenerative disease. Currently, there are no approved therapies to treat PML, and affected individuals suffer rapid motor weakness and cognitive deterioration. To identify novel therapeutic treatments for JCPyV infection, receptor agonists/antagonists identified in a previously published drug screen were evaluated for their antiviral properties. Seven drugs were selected and validated using infectivity assays, and the mechanism of inhibition was further explored for G protein coupled receptor (GPCR)-associated inhibitors due to the role of the GPCR 5-hydroxytryptamine 2 receptors (5-HT2Rs) in JCPyV entry. The inhibitors cetirizine and paroxetine both reduced infection early in the JCPyV infectious cycle. Paroxetine specifically reduced viral internalization through altering the receptor density of 5-HT2CR, inhibiting β-arrestin recruitment to the receptor, and reducing MAPK signaling through ERK. These findings highlight the potential of receptor signaling and viral entry mechanisms as possible targets for antiviral drug development. Further, this research suggests that FDA-approved receptor agonists/antagonists currently used to treat other medical conditions could be repurposed into antivirals for the possible treatment of JCPyV infection and the fatal disease PML.

virology
A Novel CMV-Specific TCR-T Cell Therapy is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Xingyu Cao,Guangna Liu,Jianping Zhang,Yanli Zhao,Hua Chen,Hongli Zheng,Wei Rui,Lemei Jia,Xueqiang Zhao,Xin Lin,Peihua Lu

DOI: https://doi.org/10.1182/blood-2021-146446

IF: 20.3

2021-01-01

Blood

Abstract:Abstract Background Cytomegalovirus (CMV) infection is an important infectious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) due to the immune-suppressive state of the transplant recipient. Patients are likely to be resistant to traditional antiviral drugs, such as ganciclovir and foscarnet, or have intolerable adverse reactions to these drugs, including bone marrow suppression and nephrotoxicity. CMV-specific CD8 + and CD4 + T-cell functional defects are the main reasons for the emergence of refractory CMV infection. Thus, it is possible to cure refractory CMV infection using CMV-specific TCR-T cell therapy via a direct antiviral effect and indirect T cell mediated immune reconstruction. Objectives and Methods We conducted a single-arm, open-label, phase I clinical trial (https://clinicaltrials.gov, NCT04153279) at the Hebei Yanda Lu Daopei Hospital. This study was designed to assess the safety and feasibility of CMV-specific TCR-T cell therapy in allo-HSCT patients with refractory CMV viremia or viral disease. We screened multiple TCRs with specificity for CMV-PP65 or IE1 polypeptides restricted by HLA-A*11:01, 24:02 and 02:01, and constructed lentiviral vectors containing CMV-specific TCRs. Peripheral blood (PB) stem cells were obtained from healthy HSCT donors for the TCR-T cell preparation. After stimulation for 24 hours, T-cells were infected with lentivirus carrying HLA-matched CMV TCR, then cultured with medium containing IL-7/IL-15 for a total of 7-9 days before harvest. After infusion, CMV TCR-T cell proliferation and persistence in PB was detected by Q-PCR. Results From December 24, 2019 to January 1, 2021, 9 patients were enrolled and as a result 7 patients including 5 with refractory CMV viremia and 2 with CMV disease successfully received the TCR-T therapy. Among the 7 patients who received TCR-T, the median age was 11 years (5-45 years of age) and 5 were male (71.4%). The diagnosis included 5 cases of acute lymphoblastic leukemia (ALL), 1 case of acute myeloid leukemia (AML) and 1 case of mixed phenotype acute leukemia (MPAL) . Patients underwent either haplo-identical transplantation (n=6) or unrelated donor transplantation (n=1). The median time for patients to CMV viremia diagnosis was 28 days (21-231 days). Patients received a median dose of 3 × 10 5 TCR-T cells/kg body weight (1-10 × 10 5 TCR-T cells/kg body weight). The mean proportion of CMV-specific TCR-T in the cultured cell products was 35.5% (18.0-68.9%). Among the 7 patients, successful follow up and data evaluation was available for 6 patients. One patient (P3) withdrew early due to uncontrolled lung infection. The median follow-up time for the entire cohort after HSCT was 199 days (144-479 days). Only 1 patient experienced Grade 1/2 cytokine release syndrome (CRS) with mild hypotension and fever. No immune effector cell-associated neurotoxicity syndrome (ICANS) or TCR-T cell-related graft-versus-host disease (GVHD) occurred in any patient. A total of 6 patients achieved complete response (CMV DNA-negative plasma) after TCR-T cell infusion. The median time from CMV-specific TCR-T infusion to the first CMV clearance was 41 days (19-91 days). The median time for CMV TCR-T cells to reach their first peak was 21 days (10-28 days) with a median copy number of 3.85×10 4 copies/μg genomic DNA (range: 1.93×10 4-7.75×10 4 copies/μg DNA) (Figure 1). CMV TCR T-cells persisted up to 3 months with detectable copy number. The levels of cytokines IL-2, TNF-α, IL-6, IL-8 and IFN-γ in PB were relatively low. Conclusion This study demonstrates the safety and feasibility of CMV-specific TCR-T cells for refractory CMV infection after HSCT. We show that adoptive transfer of CMV-specific TCR-T cells can lead to complete CMV clearance in patients who have undergone hematopoietic stem cell transplantation (HSCT) and with good tolerability and safety. Longer-term observation of these patients and larger patient studies are warranted to demonstrate the efficacy and safety of CMV TCR-T cells. Given that immune defect-related CMV infections are common and life threatening for HSCT patients, we see a potential future for CMV-specific TCR-T cell therapy for the treatment and prevention of CMV infection following HSCT or other organ transplantation. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting

Thomas Pfeiffer,Ifigeneia Tzannou,Mengfen Wu,Carlos Ramos,Ghadir Sasa,Caridad Martinez,Premal Lulla,Robert A. Krance,Lauren Scherer,Daniel Ruderfer,Swati Naik,Claire Bocchini,Iain P. Fraser,Badrish Patel,Dany Ward,Tao Wang,Helen E. Heslop,Ann M. Leen,Bilal Omer

DOI: https://doi.org/10.1158/1078-0432.ccr-22-2415

IF: 13.801

2023-01-13

Clinical Cancer Research

Abstract:Purpose: Viral infections are a major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (allo-HCT). In the absence of safe and effective antiviral treatments, virus-specific T cells have emerged as a promising therapeutic option. Posoleucel is a multivirus-specific T-cell therapy for off-the-shelf use against six viral infections that commonly occur in allo-HCT recipients: adenovirus, BK virus (BKV), cytomegalovirus, Epstein–Barr virus, human herpes virus-6, and JC virus. Patients and Methods: We conducted an open-label, phase II trial to determine the feasibility and safety of posoleucel in allo-HCT recipients infected with one or more of these viruses. Infections were either unresponsive to or patients were unable to tolerate standard antiviral therapies. Fifty-eight adult and pediatric patients were enrolled and treated. Results: Posoleucel was well tolerated, with no cytokine release syndrome or other infusion-related toxicities; two patients (3.4%) developed Grade 2 and one patient (1.7%) Grade 3 GvHD during the trial. The overall response rate 6 weeks after the first posoleucel infusion was 95%, with a median plasma viral load reduction of 97%. Of the 12 patients who had two or more target viral infections identified at study entry, 10 (83%) had a clinical response for all evaluable viruses. Of the 23 patients treated for refractory BKV-associated hemorrhagic cystitis, 74% had resolution of symptoms and macroscopic hematuria by 6 weeks post-infusion. Conclusions: In this open-label trial, treatment of refractory viral infections/disease in allo-HCT recipients with posoleucel was feasible, safe, and effective.

oncology
Passive control of uncertain multiple input-delayed systems using reduction method

X. Lou,B. Cui

DOI: https://doi.org/10.1016/j.matcom.2010.04.021

IF: 3.601

2010-08-01

Mathematics and Computers in Simulation

Abstract:

Polymorphic behavior of gram-negative bacteria membranes

Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy

A comparison between the direct and the indirect fractional order closed-loop bias eliminated least squares method

Beyond antivirals: virus-specific T-cell immunotherapy for BK virus haemorrhagic cystitis and JC virus progressive multifocal leukoencephalopathy

Antigen-Specific T Cell Receptor Discovery for Treating Progressive Multifocal Leukoencephalopathy

Density functional theory calculations on the thermodynamic properties of polynitrosoprismanes

Case report: JC polyomavirus nephropathy in simultaneous heart–kidney transplantation: the role of viral-specific in situ hybridization staining

Adenovirus‐ and cytomegalovirus‐specific adoptive T‐cell therapy in the context of hematologic cell transplan or HIV infection – A single‐center experience

JCV granule cell neuronopathy: A rare case manifestation

Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature

Angina pectoris beim Leiomyom

Cell killing and mutagenesis by 8‐methoxypsoralen in mammalian (rodent) cells

Achievement of disease control with donor-derived EB virus-specific cytotoxic T cells after allogeneic peripheral blood stem cell transplantation for aggressive NK-cell leukemia

Differentiation of highly pathogenic strains of human JC polyomavirus in neurological patients by next generation sequencing

A hybrid model based on ANFIS and adaptive expectation genetic algorithm to forecast TAIEX

Biomarkers for progressive multifocal leukoencephalopathy: emerging data for use of JC virus DNA copy number in clinical trials

Efficacy of pp65‐specific TCR‐T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation

GPCR Inhibitors Have Antiviral Properties against JC Polyomavirus Infection

A Novel CMV-Specific TCR-T Cell Therapy is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting

Passive control of uncertain multiple input-delayed systems using reduction method